Provided by Tiger Trade Technology Pte. Ltd.

Absci Corporation.

8.24
-0.4100-4.74%
Post-market: 8.240.00000.00%16:01 EDT
Volume:3.02M
Turnover:24.96M
Market Cap:1.41B
PE:-10.30
High:8.56
Open:8.38
Low:8.02
Close:8.65
52wk High:12.06
52wk Low:2.24
Shares:171.61M
Float Shares:156.49M
Volume Ratio:1.22
T/O Rate:1.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7999
EPS(LYR):-0.8421
ROE:-57.72%
ROA:-34.10%
PB:5.75
PE(LYR):-9.78

Loading ...

Top Midday Gainers

MT Newswires Live
·
Jun 25

Sector Update: Healthcare Stocks Rise Pre-Bell Wednesday

MT Newswires Live
·
Jun 24

U.S. Stocks on the Move-take-two, Wendy's, Absci

Reuters
·
Jun 24

Absci Rises on Positive Hair-loss Drug Data

Reuters
·
Jun 24

Absci Corp Shares up 14% Premarket After Co Reports Early-stage Trial Data from Its Ai-designed Hair Loss Drug

THOMSON REUTERS
·
Jun 24

Absci prices 13.5M shares at $7.41 in public offering

TIPRANKS
·
Jun 24

Absci reports Phase 1 data from human trial of ABS-201

TIPRANKS
·
Jun 24

Absci Prices 13,495,277-share Follow-on Offering at $7.41 Per Share to Raise $100 Million

Reuters
·
Jun 24

Absci Corp - Prices Underwritten Offering of 13.5 Mln Shares at $7.41 Per Share

THOMSON REUTERS
·
Jun 24

Absci Corp - Eli Lilly & Company and Others Participate in $100 Mln Absci Offering

THOMSON REUTERS
·
Jun 24

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

THOMSON REUTERS
·
Jun 24

Absci Reports Positive Interim Phase 1 Data for Abs-201 Antibody in Headline Trial

Reuters
·
Jun 24

Absci Corp - Abs-201 Half-life Estimated at Least 65 Days Supports Infrequent Dosing

THOMSON REUTERS
·
Jun 24

Absci Corp - Abs-201 Well Tolerated with Favorable Safety Data in All Sad Cohorts

THOMSON REUTERS
·
Jun 24

Absci Announces Positive Interim Phase 1 Data from the Headline™ Trial of Abs-201, a Novel Antibody Targeting the Prolactin Receptor (prlr)

THOMSON REUTERS
·
Jun 24

Absci Corp - First Multiple Ascending Dose Cohort of Abs-201 Initiated in Aga Participants

THOMSON REUTERS
·
Jun 24

Absci Corp: Full Proof-of-concept Data Anticipated in Early 2027

THOMSON REUTERS
·
Jun 24

Absci Corp - no Serious Adverse Events Reported in Abs-201 Phase 1 Interim Data

THOMSON REUTERS
·
Jun 24

Absci Is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 15

Nu, Broadcom, UNH, AbSci, TMC Trending With Analysts

TIPRANKS
·
Jun 06